KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Expenses (2016 - 2025)

Alnylam Pharmaceuticals' Operating Expenses history spans 17 years, with the latest figure at $965.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 38.23% year-over-year to $965.3 million; the TTM value through Dec 2025 reached $3.2 billion, up 32.46%, while the annual FY2025 figure was $3.2 billion, 32.46% up from the prior year.
  • Operating Expenses reached $965.3 million in Q4 2025 per ALNY's latest filing, up from $881.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $965.3 million in Q4 2025 to a low of $360.0 million in Q1 2022.
  • Average Operating Expenses over 5 years is $556.2 million, with a median of $537.2 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: decreased 1.05% in 2022, then skyrocketed 52.48% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $453.1 million in 2021, then increased by 15.57% to $523.6 million in 2022, then rose by 6.2% to $556.1 million in 2023, then increased by 25.57% to $698.3 million in 2024, then soared by 38.23% to $965.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Operating Expenses are $965.3 million (Q4 2025), $881.0 million (Q3 2025), and $789.9 million (Q2 2025).